Britain's biggest drugmaker said on Thursday the research was being accelerated with funding from an international consortium, reflecting mounting concern over the worst-ever outbreak of the disease in West Africa that has killed more than 1,500 people.
The candidate vaccine, which is being co-developed with the U.S. National Institutes of Health (NIH), is expected to be given to healthy volunteers in Britain and the United States from around mid-September, with the program then being extended to volunteers in Gambia and Mali.
source: interaksyon.com
